Ask AI
ProCE Banner Activity

TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care

Podcast

Tenosynovial giant cell tumor (TGCT) can present significant diagnostic and management challenges, particularly in patients with diffuse disease where symptoms, functional limitations, and risk of recurrence may substantially affect quality of life. In this podcast, expert faculty discuss the evolving TGCT treatment landscape, including the biologic rationale for targeting the CSF1/CSF1R pathway, the role of imaging and multidisciplinary care, patient-centered treatment goals, and practical considerations for integrating surgery and systemic therapies into individualized management strategies.

Released: August 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists, physician associates, nurses, nurse practitioners, clinical nurse specialists, pharmacists, and other healthcare professionals who care for patients with tenosynovial giant cell tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the distinguishing clinical, radiologic, and pathologic features of localized and diffuse TGCT to support timely and accurate diagnosis

  • Evaluate current and emerging data on CSF1R-targeted therapies to inform treatment selection and sequencing for patients with TGCT

  • Coordinate multidisciplinary care approaches that involve key specialties to optimize TGCT treatment planning

  • Implement evidence-based strategies to monitor for and manage adverse events associated with CSF1R-targeted therapies, including hepatotoxicity and functional impact

Financial Disclosures

Primary Author

Emanuela Palmerini, MD, PhD: consultant/advisor/speaker: Daiichi Sankyo, Deciphera, EMD Serono, Servier, SpringWorks.

William Tap, MD: other financial or material support: Cogent; consultant/advisor/speaker: Aadi, Abbisko, Boehringer Ingelheim, Curadev, Daiichi Sankyo, Deciphera, EMD Sernono, GSK, Ikena, Inhibrx, Ratio, Recordati, Synox.